FibroGen, Inc (NASDAQ:FGEN) released its earnings results on Monday. The biopharmaceutical company reported ($0.48) earnings per share for the quarter, missing the consensus estimate of ($0.47) by $0.01, Morningstar.com reports. FibroGen had a negative net margin of 37.60% and a negative return on equity of 36.41%. The firm had revenue of $29 million during the quarter, compared to the consensus estimate of $34.80 million.

FibroGen (NASDAQ:FGEN) traded up 48.20% during trading on Tuesday, reaching $49.50. 6,692,389 shares of the company’s stock were exchanged. The firm’s market cap is $3.46 billion. FibroGen has a 12 month low of $15.60 and a 12 month high of $51.45. The firm’s 50-day moving average price is $32.84 and its 200-day moving average price is $27.51.

Several equities analysts recently weighed in on the stock. Leerink Swann reissued an “outperform” rating and issued a $82.00 target price (up from $52.00) on shares of FibroGen in a research note on Tuesday. BidaskClub cut shares of FibroGen from a “strong-buy” rating to a “buy” rating in a research note on Monday, July 31st. Citigroup Inc. raised their target price on shares of FibroGen to $65.00 and gave the company a “top pick” rating in a research note on Tuesday. Jefferies Group LLC reissued a “buy” rating and issued a $75.00 target price on shares of FibroGen in a research note on Tuesday. Finally, Stifel Nicolaus raised their target price on shares of FibroGen from $38.00 to $80.00 and gave the company a “buy” rating in a research note on Tuesday. One research analyst has rated the stock with a sell rating, one has issued a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and a consensus price target of $56.86.

TRADEMARK VIOLATION WARNING: This story was originally posted by American Banking News and is the sole property of of American Banking News. If you are reading this story on another website, it was illegally copied and reposted in violation of US and international copyright and trademark laws. The original version of this story can be read at https://www.americanbankingnews.com/2017/08/08/fibrogen-inc-nasdaqfgen-posts-quarterly-earnings-results-misses-estimates-by-0-01-eps.html.

In other FibroGen news, CEO Thomas B. Neff sold 38,636 shares of the company’s stock in a transaction on Tuesday, May 16th. The stock was sold at an average price of $27.70, for a total value of $1,070,217.20. Following the completion of the transaction, the chief executive officer now owns 3,345,941 shares in the company, valued at approximately $92,682,565.70. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, VP Pat Cotroneo sold 28,346 shares of the company’s stock in a transaction on Wednesday, August 2nd. The shares were sold at an average price of $33.97, for a total value of $962,913.62. Following the completion of the transaction, the vice president now owns 170,666 shares of the company’s stock, valued at approximately $5,797,524.02. The disclosure for this sale can be found here. Insiders sold a total of 409,974 shares of company stock valued at $12,647,338 in the last 90 days. Corporate insiders own 14.90% of the company’s stock.

A number of hedge funds and other institutional investors have recently made changes to their positions in FGEN. Russell Investments Group Ltd. acquired a new position in shares of FibroGen during the fourth quarter worth about $462,000. Norges Bank acquired a new position in shares of FibroGen during the fourth quarter worth about $8,480,000. Teachers Advisors LLC increased its position in shares of FibroGen by 3.7% in the fourth quarter. Teachers Advisors LLC now owns 461,901 shares of the biopharmaceutical company’s stock worth $9,885,000 after buying an additional 16,544 shares during the period. Fox Run Management L.L.C. acquired a new position in shares of FibroGen during the first quarter worth about $574,000. Finally, Capital Impact Advisors LLC increased its position in FibroGen by 8.7% in the first quarter. Capital Impact Advisors LLC now owns 46,710 shares of the biopharmaceutical company’s stock valued at $1,151,000 after buying an additional 3,727 shares during the last quarter. Hedge funds and other institutional investors own 43.45% of the company’s stock.

About FibroGen

FibroGen, Inc is a science-based biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of therapeutics to treat serious unmet medical needs. Its lead product candidate is roxadustat (FG-4592). It is also engaged in developing products, such as FG-6874, FG-3019 and FG-5200.

Earnings History for FibroGen (NASDAQ:FGEN)

Receive News & Ratings for FibroGen Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FibroGen Inc and related companies with MarketBeat.com's FREE daily email newsletter.